Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial

Overview of attention for article published in JAMA Oncology, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog
twitter: 56 X users

facebook: 5 Facebook pages
googleplus: 2 Google+ users

Readers on

mendeley: 99 Mendeley
citeulike: 1 CiteULike

Summary News Blogs X Facebook Google+

So far, Altmetric has seen 2 news stories from 2 outlets.

KIT Mutations Linked to Imatinib Response in GIST

Medscape, 03 Apr 2017

Reuters Health Information By Will Boggs MD | April 03, 2017 NEW YORK (Reuters Health) - Different KIT mutations have various…

Optimal adjuvant imatinib duration influenced by KIT mutation status

medwireNews, 03 Apr 2017

medwireNews: Patients with gastrointestinal stromal tumors (GISTs) harboring KIT proto-oncogene receptor tyrosine kinase exon…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.